CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer...
Phase 2
Columbus, Ohio, United States and 16 other locations
open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic...
Phase 1, Phase 2
Columbus, Ohio, United States and 15 other locations
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS muta...
Phase 1
Columbus, Ohio, United States and 22 other locations
or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have recei...
Phase 2, Phase 3
Columbus, Ohio, United States and 91 other locations
The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors...
Phase 1
Columbus, Ohio, United States and 7 other locations
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors th...
Phase 2
Columbus, Ohio, United States and 122 other locations
This is a single arm phase II study. All patients will receive 3 cycles of the treatment of nab-paclitaxel (Days 1, 8 and 15), gemcitabine (Days 1, 8...
Phase 2
Columbus, Ohio, United States
This is a Phase 2, multicenter, open-label, 3-arm, randomized, parallel group study to evaluate the efficacy and safety of TTX-030 with or without bu...
Phase 2
Columbus, Ohio, United States and 67 other locations
anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors...
Phase 1, Phase 2
Columbus, Ohio, United States and 36 other locations
This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8...
Phase 1
Columbus, Ohio, United States and 7 other locations
Clinical trials
Research sites
Resources
Legal